Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?

Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow r...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2007-04, Vol.21 (2), p.99
Main Authors: Togni, Mario, Vigorito, Francesco, Windecker, Stephan, Abrecht, Linda, Wenaweser, Peter, Cook, Stephane, Billinger, Michael, Meier, Bernhard, Hess, Otto M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 2
container_start_page 99
container_title Cardiovascular drugs and therapy
container_volume 21
creator Togni, Mario
Vigorito, Francesco
Windecker, Stephan
Abrecht, Linda
Wenaweser, Peter
Cook, Stephane
Billinger, Michael
Meier, Bernhard
Hess, Otto M
description Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow. Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow. CFR at rest was 3.0+/-0.6 in controls and 2.1+/-0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4+/-0.7, 3.9+/-0.9, and 4.0+/-0.1 (p
doi_str_mv 10.1007/s10557-006-0494-7
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_213847159</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1278756071</sourcerecordid><originalsourceid>FETCH-proquest_journals_2138471593</originalsourceid><addsrcrecordid>eNqNi8sOwUAUQCdCoh4fYDexH-70NZ2VUBo2FmInItVcoSa9zBTx9yx8gNVZnHMYG0gYSQA1dhKiSAmAWECoQ6EazJORCoTyQ9lkHmgfROBD3GYd50r4PlonHpvOCR2vz8h3R6zzvZgZKq5o-RqPlycZMnxVFRZzhzwlS1Vu3zwz9OIbdGifOOmx1ik3Dvs_dtkwW2zTpbhZuj_Q1YeSHrb6qoMvgyRUMtLBX9EH7wA-9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213847159</pqid></control><display><type>article</type><title>Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?</title><source>Springer Nature</source><creator>Togni, Mario ; Vigorito, Francesco ; Windecker, Stephan ; Abrecht, Linda ; Wenaweser, Peter ; Cook, Stephane ; Billinger, Michael ; Meier, Bernhard ; Hess, Otto M</creator><creatorcontrib>Togni, Mario ; Vigorito, Francesco ; Windecker, Stephan ; Abrecht, Linda ; Wenaweser, Peter ; Cook, Stephane ; Billinger, Michael ; Meier, Bernhard ; Hess, Otto M</creatorcontrib><description>Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow. Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow. CFR at rest was 3.0+/-0.6 in controls and 2.1+/-0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4+/-0.7, 3.9+/-0.9, and 4.0+/-0.1 (p&lt;0.01) in controls, and to 2.3+/-0.7, 2.6+/-0.9, and 2.6+/-0.5 (p&lt;0.05) in CAD patients. CFI decreased significantly with intracoronary nebivolol and correlated to changes in heart rate (r=0.75, p&lt;0.001) and rate-pressure product (r=0.59, p=0.001). Intracoronary nebivolol is associated with a significant increase in CFR due to reduction in resting flow (controls), or due to an increase in maximal coronary flow (CAD patients). CFI decreased with nebivolol parallel to the reduction in myocardial oxygen consumption.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-006-0494-7</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer Nature B.V</publisher><ispartof>Cardiovascular drugs and therapy, 2007-04, Vol.21 (2), p.99</ispartof><rights>Springer Science+Business Media, LLC 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Togni, Mario</creatorcontrib><creatorcontrib>Vigorito, Francesco</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Abrecht, Linda</creatorcontrib><creatorcontrib>Wenaweser, Peter</creatorcontrib><creatorcontrib>Cook, Stephane</creatorcontrib><creatorcontrib>Billinger, Michael</creatorcontrib><creatorcontrib>Meier, Bernhard</creatorcontrib><creatorcontrib>Hess, Otto M</creatorcontrib><title>Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?</title><title>Cardiovascular drugs and therapy</title><description>Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow. Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow. CFR at rest was 3.0+/-0.6 in controls and 2.1+/-0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4+/-0.7, 3.9+/-0.9, and 4.0+/-0.1 (p&lt;0.01) in controls, and to 2.3+/-0.7, 2.6+/-0.9, and 2.6+/-0.5 (p&lt;0.05) in CAD patients. CFI decreased significantly with intracoronary nebivolol and correlated to changes in heart rate (r=0.75, p&lt;0.001) and rate-pressure product (r=0.59, p=0.001). Intracoronary nebivolol is associated with a significant increase in CFR due to reduction in resting flow (controls), or due to an increase in maximal coronary flow (CAD patients). CFI decreased with nebivolol parallel to the reduction in myocardial oxygen consumption.</description><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNi8sOwUAUQCdCoh4fYDexH-70NZ2VUBo2FmInItVcoSa9zBTx9yx8gNVZnHMYG0gYSQA1dhKiSAmAWECoQ6EazJORCoTyQ9lkHmgfROBD3GYd50r4PlonHpvOCR2vz8h3R6zzvZgZKq5o-RqPlycZMnxVFRZzhzwlS1Vu3zwz9OIbdGifOOmx1ik3Dvs_dtkwW2zTpbhZuj_Q1YeSHrb6qoMvgyRUMtLBX9EH7wA-9Q</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>Togni, Mario</creator><creator>Vigorito, Francesco</creator><creator>Windecker, Stephan</creator><creator>Abrecht, Linda</creator><creator>Wenaweser, Peter</creator><creator>Cook, Stephane</creator><creator>Billinger, Michael</creator><creator>Meier, Bernhard</creator><creator>Hess, Otto M</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20070401</creationdate><title>Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?</title><author>Togni, Mario ; Vigorito, Francesco ; Windecker, Stephan ; Abrecht, Linda ; Wenaweser, Peter ; Cook, Stephane ; Billinger, Michael ; Meier, Bernhard ; Hess, Otto M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2138471593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Togni, Mario</creatorcontrib><creatorcontrib>Vigorito, Francesco</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Abrecht, Linda</creatorcontrib><creatorcontrib>Wenaweser, Peter</creatorcontrib><creatorcontrib>Cook, Stephane</creatorcontrib><creatorcontrib>Billinger, Michael</creatorcontrib><creatorcontrib>Meier, Bernhard</creatorcontrib><creatorcontrib>Hess, Otto M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Togni, Mario</au><au>Vigorito, Francesco</au><au>Windecker, Stephan</au><au>Abrecht, Linda</au><au>Wenaweser, Peter</au><au>Cook, Stephane</au><au>Billinger, Michael</au><au>Meier, Bernhard</au><au>Hess, Otto M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><date>2007-04-01</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>99</spage><pages>99-</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>Nebivolol, a highly selective beta1-adrenergic receptor-blocker, increases basal and stimulated endothelial nitric oxide (NO)-release. It is unknown, whether coronary perfusion is improved by the increase in NO availability. Therefore, we sought to evaluate the effect of nebivolol on coronary flow reserve (CFR) and collateral flow. Doppler-flow wire derived coronary flow velocity measurements were obtained in ten controls and eight patients with coronary artery disease (CAD) at rest and after intracoronary nebivolol. CFR was defined as maximal flow during adenosine-induced hyperemia divided by resting flow. In the CAD group, collateral flow was determined after dilatation of a flow-limiting coronary stenosis. Collateral flow index (CFI) was defined as the ratio of flow velocity during balloon inflation divided by resting flow. CFR at rest was 3.0+/-0.6 in controls and 2.1+/-0.4 in CAD patients. After intracoronary doses of 0.1, 0.25, and 0.5 mg nebivolol, CFR increased to 3.4+/-0.7, 3.9+/-0.9, and 4.0+/-0.1 (p&lt;0.01) in controls, and to 2.3+/-0.7, 2.6+/-0.9, and 2.6+/-0.5 (p&lt;0.05) in CAD patients. CFI decreased significantly with intracoronary nebivolol and correlated to changes in heart rate (r=0.75, p&lt;0.001) and rate-pressure product (r=0.59, p=0.001). Intracoronary nebivolol is associated with a significant increase in CFR due to reduction in resting flow (controls), or due to an increase in maximal coronary flow (CAD patients). CFI decreased with nebivolol parallel to the reduction in myocardial oxygen consumption.</abstract><cop>Dordrecht</cop><pub>Springer Nature B.V</pub><doi>10.1007/s10557-006-0494-7</doi></addata></record>
fulltext fulltext
identifier ISSN: 0920-3206
ispartof Cardiovascular drugs and therapy, 2007-04, Vol.21 (2), p.99
issn 0920-3206
1573-7241
language eng
recordid cdi_proquest_journals_213847159
source Springer Nature
title Does the [beta]-Blocker Nebivolol Increase Coronary Flow Reserve?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T20%3A15%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20the%20%5Bbeta%5D-Blocker%20Nebivolol%20Increase%20Coronary%20Flow%20Reserve?&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Togni,%20Mario&rft.date=2007-04-01&rft.volume=21&rft.issue=2&rft.spage=99&rft.pages=99-&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/s10557-006-0494-7&rft_dat=%3Cproquest%3E1278756071%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_2138471593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213847159&rft_id=info:pmid/&rfr_iscdi=true